Prophylactic and therapeutic treatment of EAE with MOG-DNA vaccination ameliorates the clinical signs of the disease. EAE was induced in female C57BL6/J mice with MOG35-55 peptide in CFA. Mice were vaccinated with i.m. injections of 100 μg of DNA according to prophylactic (A) or therapeutic (D) protocols, as described in Methods. Two groups of mice (n = 5) were subjected to DNA treatment with the full-length MOG-DNA construct (□) or plasmid control (■) in prophylactic (B) or therapeutic (E) settings. Disease parameters in mice treated prophylactically and therapeutically are shown in tables (C and F). Mean clinical scores are plotted against the number of days after EAE induction. Disease scores are expressed as mean values (SEM). aIndicates cumulative disease scores at 30 days p.i.; statistically significant differences obtained by Student’s t-tests are denoted with asterisks (*p < 0.05; **p < 0.005). Results shown are representative of two independent experiments.